Lataa...
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not ach...
Tallennettuna:
| Julkaisussa: | Pharmaceutics |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7151083/ https://ncbi.nlm.nih.gov/pubmed/32178288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12030256 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|